Bladder adenocarcinoma

Astrocytic tumor Barrett s adenocarcinoma Bladder carcinoma Breast carcinoma... 

Because evidence of carcinogenicity in mice (leiomyosarcoma in the urinary bladder, lymphoblastic lymphosarcoma and leukemia, and bronchiolar-alveolar adenocarcinoma and adenoma) was obtained from a single study, it is considered that there is limited evidence of carcinogenicity effects, which deserves a classification Category 2-H350 according to CLP criteria [63],... 

Pretreatment of human T24 bladder or human colorectal adenocarcinoma cells with 5-FU followed by CGP 41251 showed a synergistic drug interaction in both cell lines (Fabbro et al., 1999). CGP 41251 or 5rFU were ineffective as a single agent against COLO 205 tumors up to 200 mg/kg/day p.o. and 75 mg/kg/week i. v., respectively. Combination of both compounds at these concentrations showed significant antitumor activity in this tumor model (Fabbro et al., 1999). 

Fluorouracil is used in several combination regimens in the treatment of breast cancer. It also has palliative activity in gastrointestinal adenocarcinomas, including those originating in the stomach, pancreas, liver, colon, and rectum. Other tumors in which some antitumor effects have been reported include carcinomas of the ovary, cervix, oropharynx, bladder, and prostate. Topical 5-fluorouracil cream has been useful in the treatment of premalignant keratoses of the skin and superficial basal cell carcinomas, but it should not be used in invasive skin cancer. 

Doxorubicin is one of the most effective agents used in the treatment of carcinomas of the breast, ovary, endometrium, bladder, and thyroid and in oat cell cancer of the lung. It is included in several combination regimens for diffuse lymphomas and Hodgkin s disease. Doxorubicin can be used as an alternative to daunorubicin in acute leukemias and is useful in Ewing s sarcoma, osteogenic sarcoma, soft-tissue sarcomas, and neuroblastoma. Some activity has been reported in non-oat cell lung cancer, multiple myeloma, and adenocarcinomas of the stomach, prostate, and testis. 

Breast, ovarian, cervical, bladder and prostate cancer gastrointestinal adenocarcinomas Metastatic pancreatic cancer small cell lung cancer Leukemia Breast cancer... 

Chronic study (mouse) Mammary gland adenocarcinoma, liver necrosis, urinary bladder hyperplasia (640 mg kg-1 per day) Kidney lesions (62.5 mg kg-1 per day)... 

Tumors of the bladder F ibroepitheliomas Solid carcinomas Adenocarcinomas Spindle-shaped carcinomas... 

ET-1 is the only isoform secreted by endothelial cells. However, ET-1 and ET-3 are found in varying proportions in a wide range of tissues including brain, lung, kidney, spleen, liver, gut and bladder [5], ET-2 has been found in a human adenocarcinoma cell line [6]. 

Tumors that are characteristically strongly and diffusely positive include those of the salivary glands, lung, breast, ovary, endometrium, bladder, and thymus, as well as mesotheliomas, neuroendocrine tumors, pancreaticobili-ary adenocarcinomas, and the fibrolamellar variant of hepatocellular carcinoma. 33 CK7 is also typically expressed in tumor cells of mammary and extramammary Paget disease. 34... 

Primary adenocarcinomas of the lung are typically CK7-F, CK20-, and CEA-f, whereas colorectal carcinomas are CK7-, CK20-F, and CEA-i- ductal and lobular breast carcinomas are CK7-f, CK20-, and often CEA-I- and ovarian carcinomas are CK7-I-, CK20 , and CEA-.121,125-129,224-227 Neoplasms that typically are strongly positive for most CEA antibodies include adenocarcinomas of the lung, colon, stomach, biliary tree, pancreas, urinary bladder, endocervix, paranasal... 

Adenocarcinomas of urinary bladder (urachal origin) are CDX2-I- but are also positive for thrombomodulin and CK7, whereas colorectal carcinomas are negative with thrombomodulin and CK7 and have nuclear beta-catenin expression. 

True hepatocellular carcinoma differentiation (polyclonal CEA-I-, HepPar-l-i-, sinusoidal cell CD34-f) has been described on rare occasions as a component of some adenocarcinomas from urinary bladder and stomach. Hepatoid carcinomas as components of ovarian tumors regularly express significant HepPar-1. ... 

Wang HL, Lu DW, Yerian LM, et al. Immunohistochemical distinction between primary adenocarcinoma of the bladder and secondary colorectal adenocarcinoma. Am J Surg Pathol. 2001 25 1380-1387. 

Sinard J, Macleay Jr L, Melamed J. Hepatoid adenocarcinoma in the urinary bladder. Unusual localization of a newly recognized tumor type. Cancer. 1994 73 1919-1925. 

Mhawech P, Uchida T, Pelte MF. Immunohistochemical profile of high-grade urothelial bladder carcinoma and prostate adenocarcinoma. Hum Pathol. 2002 33 1136-1140. 

Sainz and colleagues studied the presence of Nap-A in 967 lung neoplasms. The authors found that less than 5% of carcinomas of the bladder, pancreas, breast, liver, biliary tract, colon, ovary, uterus, lung squamous cell carcinoma, and lung small cell carcinoma were positive for Nap-A and that 74% of lung adenocarcinomas were positive for Nap-A versus 63% positive for... 

TTF-1. Also, 11% of lung adenocarcinomas detected by Nap-A were missed by TTF-1 staining. The authors concluded that Napsin A was a valuable marker for detecting lung adenocarcinomas versus other adenocarcinomas such as those from the breast, colon, biliary tract, pancreas, urinary bladder, and ovary. It was less useful in distinguishing primary pulmonary adenocarcinomas from thyroid carcinomas and renal carcinomas. 

Adenocarcinoma, colorectal, 4 metastatic Carcinoma, small cell, bladder 34... 

Lopez-Beltran A, Luque RJ, Quintero A, et al. Hepatoid adenocarcinoma of the urinary bladder. Virch Arch. 2003 442 381-387. 

Urethral and periurethral gland adenocarcinoma (female) Villous adenoma and adenocarcinoma of the bladder Extramammary Paget disease of the male external genitalia Pleomorphic adenoma of the salivary glands (male) Carcinoma of the salivary glands (male)... 

---